Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Results of Operations and Financial Condition.
Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Results of Operations and Financial Condition
On August 3, 2017, Kadmon Holdings, Inc. (the “Company”) issued a press release announcing its financial and operational results for the three and six months endedJune 30, 2017. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report.
The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18 of the Exchange Act. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, or into any filing or other document to the Exchange Act, except as otherwise expressly stated in any such filing.
|
Item 2.02 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release issued by Kadmon Holdings, Inc., dated August 3, 2017, “Kadmon Provides Business Update and Reports Second Quarter 2017 Financial Results.” |
Kadmon Holdings, Inc. ExhibitEX-99.1 2 kdmn-20170803xex99_1.htm EX-99.1 2017 Q2 Earnings release Exhibit 99.1 Kadmon Provides Business Update and Reports Second Quarter 2017 Financial Results NEW YORK,…To view the full exhibit click here
About Kadmon Holdings, Inc. (NYSE:KDMN)
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
